Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01041417 · ClinicalTrials.gov registry record · Phase 2
Granulocyte-Macrophage Stimulating Factor in the Treatment of Peripheral Arterial Disease
A Phase 2 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 2
- Development phase
- 159
- Enrollment target
NCT01041417 is a Phase 2 study that has completed, run by Emory University. The registered enrollment target is 159 participants.
The verdict
NCT01041417, a Phase 2 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 159 participants
- Enrollment target
Study Summary
Peripheral arterial disease is a common condition in older adults involving poor arterial circulation in the legs leading to leg pain and debility. The body's own circulating blood vessel stem cells may help to improve circulation. This study will test whether treatment with the drug granulocyte macrophage colony stimulating factor (GM-CSF) will improve symptoms and signs of peripheral arterial disease over placebo after four weeks of therapy. As well this study will examine whether improvements in blood vessel function can be observed. Finally, we will measure blood vessel function and stem cell levels in order to determine whether they can help to predict whether patients wither peripheral arterial disease will suffer further cardiovascular complications.
Interventions
- DRUG Placebo
- DRUG Granulocyte-Macrophage Stimulating Factor (GM-CSF)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 159 participants |
| Start Date | 2009-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01041417
The ClinicalTrials.gov registry entry for NCT01041417 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 159 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01041417 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01041417 about?
NCT01041417 is a clinical study titled "Granulocyte-Macrophage Stimulating Factor in the Treatment of Peripheral Arterial Disease". Peripheral arterial disease is a common condition in older adults involving poor arterial circulation in the legs leading to leg pain and debility. The body's own circulating blood vessel stem cells may help to improve circulation. This study will test whether treatment with the drug granulocyte mac...
What is the current status of trial NCT01041417?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 159 participants. The study started on 2009-09.
What interventions are being tested in trial NCT01041417?
The interventions under investigation include: Placebo (DRUG), Granulocyte-Macrophage Stimulating Factor (GM-CSF) (DRUG).
Who is sponsoring clinical trial NCT01041417?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.